Mason Morfit, ValueAct Capital
G. Mason Morfit is President of ValueAct Capital (“VAC”), a governance-oriented investment fund with approximately $12.5 billion in assets under management. ValueAct Capital invests in a concentrated portfolio of public companies and works actively with their executives and boards of directors on issues of strategy, capital structure, M&A and talent management. The partners at ValueAct Capital have served on the Boards of Directors of 32 public companies. VAC also has the flexibility to execute going-private transactions for 100% control in select circumstances. Mr. Morfit is a director of Valeant Pharmaceuticals International (Valeant), and Microsoft, Inc. The innovative executive compensation structure he designed as Chairman of the Compensation Committee at Valeant was featured in the Wall St. Journal and several academic papers. He is a former director of CR Bard, Inc., Immucor, Inc., Advanced Medical Optics, Solexa, Inc. and MSD Performance, Inc.